EPISODE · Mar 18, 2026 · 18 MIN
ImmuPharma CEO on P140 progress and expanded pipeline with Kapiglucagon
from Proactive - Interviews for investors · host Proactive Investors
ImmuPharma PLC (AIM:IMM, FRA:25I) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company's latest developments, including progress on its lead asset P140, a newly accelerated program for Kapiglucagon, and recent fundraising activity. McCarthy emphasised that P140 remains the company’s primary focus, with ongoing licensing discussions described as highly active. He stated, “We are delivering a deal this year. We're confident of doing that,” highlighting continued engagement with multiple potential partners, including new parties that have approached the company since late 2025. Alongside this, ImmuPharma has advanced Kapiglucagon into an accelerated development program following interest and funding support from existing shareholders. The asset, targeting Type 1 diabetes (T1D), is designed to address limitations in current glucose delivery systems. McCarthy explained that Kapiglucagon offers improved solubility and stability, making it suitable for next-generation dual hormone pumps. The company has secured funding led by Lanstead Capital Investors to support a two-year development plan, with the goal of progressing Kapiglucagon toward potential licensing discussions. McCarthy noted that early engagement with industry players has already generated strong interest. On top of the £6 million raised through a subscription with Lanstead, a further £1.5 million may be raised through a retail offer opening today via the Winterflood Retail Access Platform (WRAP), giving existing and new UK investors the opportunity to participate at the same price of 6.0 pence per share, a 13.7% discount to the previous closing price. Despite the expansion of its pipeline, McCarthy reiterated that the company’s strategy remains centred on P140, stating that “our total focus has not been diverted one iota in pushing forward those license discussions.” For more insights into ImmuPharma’s strategy and upcoming milestones, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #ImmuPharma #TimMcCarthy #P140 #Kapiglucagon #BiotechNews #PharmaNews #DrugDevelopment #DiabetesResearch #Type1Diabetes #BiotechInvesting #HealthcareInnovation #ClinicalDevelopment #LicensingDeals #SmallCapStocks #AIMStocks
What this episode covers
ImmuPharma PLC (AIM:IMM, FRA:25I) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company's latest developments, including progress on its lead asset P140, a newly accelerated program for Kapiglucagon, and recent fundraising activity. McCarthy emphasised that P140 remains the company’s primary focus, with ongoing licensing discussions described as highly active. He stated, “We are delivering a deal this year. We're confident of doing that,” highlighting continued engagement with multiple potential partners, including new parties that have approached the company since late 2025. Alongside this, ImmuPharma has advanced Kapiglucagon into an accelerated development program following interest and funding support from existing shareholders. The asset, targeting Type 1 diabetes (T1D), is designed to address limitations in current glucose delivery systems. McCarthy explained that Kapiglucagon offers improved solubility and stability, making it suitable for next-generation dual hormone pumps. The company has secured funding led by Lanstead Capital Investors to support a two-year development plan, with the goal of progressing Kapiglucagon toward potential licensing discussions. McCarthy noted that early engagement with industry players has already generated strong interest. On top of the £6 million raised through a subscription with Lanstead, a further £1.5 million may be raised through a retail offer opening today via the Winterflood Retail Access Platform (WRAP), giving existing and new UK investors the opportunity to participate at the same price of 6.0 pence per share, a 13.7% discount to the previous closing price. Despite the expansion of its pipeline, McCarthy reiterated that the company’s strategy remains centred on P140, stating that “our total focus has not been diverted one iota in pushing forward those license discussions.” For more insights into ImmuPharma’s strategy and upcoming milestones, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #ImmuPharma #TimMcCarthy #P140 #Kapiglucagon #BiotechNews #PharmaNews #DrugDevelopment #DiabetesResearch #Type1Diabetes #BiotechInvesting #HealthcareInnovation #ClinicalDevelopment #LicensingDeals #SmallCapStocks #AIMStocks
NOW PLAYING
ImmuPharma CEO on P140 progress and expanded pipeline with Kapiglucagon
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.